CYTO - Why Is Allergy-Focused Altamira Therapeutics Stock Trading Over 200% Higher Today? | Benzinga
Altamira Therapeutics Ltd (NASDAQ: CYTO) entered into a binding agreement to sell a 51% stake in its subsidiary Altamira Medica AG to a Swiss private equity investor as part of its strategic repositioning around its RNA delivery technology.
Medica's key asset is Bentrio, a drug-free OTC nasal spray utilized for treating allergic rhinitis, which has been cleared by the FDA and is being commercialized in many countries.
Altamira has agreed to sell the 51% ...